Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to limited treatments approved for children. Although topical corticosteroids continue to be the mainstay of pediatric psoriasis treatment, there is an increase in biologics use owing to the more frequent and severe adverse events associated with the long-term use of topical corticosteroids in children. Use of conventional systemics also appears to be on the decline, further underscoring a growing need for treatments with more-acceptable safety profiles.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
  • How have biologics such as Cosentyx, Enbrel, Humira, Stelara, Taltz, and Tremfya been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of pediatric psoriasis patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of pediatric patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated pediatric patients with psoriasis?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, Bausch Health, Eli Lilly, Janssen, Novartis

Key drugs: Cosentyx, Elidel, Enbrel, Humira, Stelara, Taclonex, Taltz, Tremfya

Table of contents

  • Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment-Algorithms-Claims-Data-Analysis-Pediatric-Psoriasis-US-May-2021
    • Treatment Algorithms CDA Pediatric Psoriasis US 2021 Dashboard

Author(s): Mohit Nasa, M.B.A.

Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Prior to joining DRG, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.

Related Reports

Psoriasis - Current Treatment - Treatment Algorithms - Claims Data Analysis: Adult Psoriasis - Refreshed Dashboard 2021 (US)

Adult psoriasis represents an increasingly lucrative market for biologics to treat the moderate to severe population, for whom conventional systemic and topical treatments alone are not sufficient....

View Details

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

View Details

Psoriasis | Disease Landscape and Forecast | G7 | 2020

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

View Details

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details